Cequa Phase 4 Study- Dr. Pam Theriot

iPeer Review! 🔖Dr. Pam Theriot reviews results of the Cequa Phase 4 study. The phase 4 Cequa cyclosporine 0.09% solution study reveals that patients 👭who did not respond to cyclosporine 0.05% for over three months can successfully switch to 0.09%, showing significant improvement in both signs and symptoms. Conducted over 12 weeks, this multi-center🏢 study highlights the benefits of BID dosing with 0.09% cyclosporine, including decreased corneal fluorescein stain and improved symptom scores. 👀#dryeye #cequa #eyecare #optometry Refrences: Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA. Ophthalmology 360. "Phase 4 Data Demonstrates CEQUA's Sustained Efficacy in Dry Eye Disease." Available at: https://ophthalmology360.com/phase-4-data-demonstrates-cequas-sustained-efficacy-in-dry-eye-disease/ Disclosures: Dr. Theriot is a speaker for Sun Pharma.